Literature DB >> 35438460

Successful HLA-haploidentical stem cell transplantation with post-transplant cyclophosphamide in an older patient with chronic active Epstein-Barr virus infection.

Masaya Maegaki1, Koji Kawamura1,2, Kentaro Hara1, Rina Hosoda1, Sayaka Suzuki1,2, Yuzuru Hosoda1,2, Ken-Ichi Imadome3, Toru Motokura2, Tetsuya Fukuda4.   

Abstract

Chronic active Epstein-Barr virus infection (CAEBV) is a subtype of EBV-associated T/NK cell lymphoproliferative disease and is only curable by allogeneic hematopoietic stem cell transplantation. However, finding a human leukocyte antigen (HLA)-matched donor at a suitable time can sometimes be difficult. We report the case of a 60-year-old woman who received prednisolone (PSL) after being diagnosed with autoimmune hepatitis 3 years earlier. She suddenly developed high fever and impaired liver function. Based on a high EBV DNA load in the peripheral blood, CAEBV was diagnosed. The patient was started on cooling therapy with PSL, cyclosporine, and etoposide, which reduced symptoms. Subsequently, she received HLA-haploidentical stem cell transplantation (haplo-SCT) with reduced-intensity conditioning (fludarabine 25 mg/m2 for 5 days, melphalan 50 mg/m2 for 2 days, and total body irradiation at 2 Gy) and post-transplant cyclophosphamide (PTCy) because she lacked an HLA-matched donor. Liver function was restored, and EBV DNA load in peripheral white blood cells became undetectable. The patient is alive without relapse or severe complications over 1 year after transplantation. To our knowledge, this is the first report of successful haplo-SCT with PTCy for CAEBV. This approach may be an alternative therapeutic option for CAEBV patients lacking an HLA-matched donor.
© 2022. Japanese Society of Hematology.

Entities:  

Keywords:  Chronic active Epstein–Barr virus infection (CAEBV); HLA-haploidentical stem cell transplantation (haplo-SCT); Post-transplant cyclophosphamide (PTCy)

Mesh:

Substances:

Year:  2022        PMID: 35438460     DOI: 10.1007/s12185-022-03345-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.319


  2 in total

1.  Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

Authors:  R E Curtis; L B Travis; P A Rowlings; G Socié; D W Kingma; P M Banks; E S Jaffe; G E Sale; M M Horowitz; R P Witherspoon; D A Shriner; D J Weisdorf; H J Kolb; K M Sullivan; K A Sobocinski; R P Gale; R N Hoover; J F Fraumeni; H J Deeg
Journal:  Blood       Date:  1999-10-01       Impact factor: 22.113

2.  [Fatal exacerbations of chronic active Epstein-Barr virus infection subsequent to cytotoxic chemotherapy].

Authors:  Sakurako Suma; Naoki Kurita; Naoko Baba; Kantaro Ishitsuka; Shinichiro Sukegawa; Kenichi Makishima; Yusuke Kiyoki; Yumiko Maruyama; Takayasu Kato; Yasuhisa Yokoyama; Mamiko Sakata-Yanagimoto; Naoshi Obara; Yuichi Hasegawa; Shigeru Chiba
Journal:  Rinsho Ketsueki       Date:  2019
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.